ChromoCure forges co-development agreement for chromosomal scanner system ChromoCure, Inc. announced today it executed a Technology Co-Development Contract with its primary cell planning and application technology provider priligy-sverige.com/instruktioner-for-anvandning-av-priligy.html . The co-development agreement calls for the joint-advancement of a completely integrated chromosomal scanner system for nation-wide distribution to pathology and related cancers detection labs. The contract calls for the specialized collaboration and partnership between the companies and joint specialized research and development initiatives to complete a completely automated hybridization system allowing for a complete ‘end-to-end’ chromosomal scanning solution.
This is however the same for both individuals with asthma and COPD. We have found drugs that can improve symptoms and stop acute attacks of the disease, but there is absolutely no cure currently. In both asthma, and especially COPD, there are many of sub-pieces, or phenotypes, of diseases. These different patient classes seem to need partly different treatments. We’ve taken a broad-brush strategy, but we have to understand these different types of patients better, in order that we can deal with the ones that benefit the most. For patients with slight to especially moderate asthma, available drugs could be very effective.